Pfizer says Litfulo safety profile in NSV consistent with alopecia areata
PFE•Pfizer said Litfulo significantly improved facial and total-body repigmentation in patients with nonsegmental vitiligo (NSV), with a safety profile consistent with alopecia areata and no new safety signals. The company plans to submit Phase 3 data to the FDA and EMA.
1. Trial findings
Pfizer said Litfulo significantly improved facial and total-body repigmentation in patients with nonsegmental vitiligo. The company reported that the drug’s safety profile in NSV was consistent with alopecia areata, with no new safety signals.
2. Regulatory submissions
Pfizer said it plans to submit Litfulo Phase 3 data to the FDA and EMA.
